Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients

Authors

  • Hildegard T. Greinix AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Werner Linkesch AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Manfred Seifert AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Ernst Kubista AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Klaus Czerwenka AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Fariborz Elahi AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Christoph Zielinski AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Paul Hoecker AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Günther Steger AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Axel Schulenburg AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Geralt Neumeister AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Werner Rabitsch AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Raimund Jakesz AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria
  • Peter Kalhs AKH Vienna, Klinik fuer Innere I, Knochenmarktransplantation, Waehringer Guertel 18-20, A-1090 Vienna Austria.; From the Departments of Medicine I, Bone Marrow Transplantation Unit (H.T. Greinix, F. Elahi, A. Schulenburg, W. Rabitsch, P. Kalhs), Gynecology (M. Seifert, E. Kubista), Pathology (K. Czerwenka), Transfusion Medicine (P. Hoecker), Surgery (R. Jakesz), Division of Oncology, University of Vienna (C. Zielinski, G. Steger), and the Department of Hematology, University of Graz (W. Linkesch, G. Neumeister), Austria

DOI:

https://doi.org/10.1080/028418600430969

Abstract

Despite standard-dose adjuvant chemotherapy, the prognosis for patients with breast cancer and extensive axillary lymph node involvement at diagnosis is poor. The efficacy of a paclitaxel-containing, high-dose chemotherapy protocol in 21 high-risk breast cancer patients is assessed. After standard-dose chemotherapy followed by peripheral blood stem cell (PBSC) mobilization, high-dose therapy with paclitaxel, carboplatin, and cyclophosphamide and CD34-selected PBSC rescue was given. Hematologic reconstitution after high-dose therapy was rapid. Main toxicity included diarrhea grade I or II in about half of the patients and infections were observed in 19%. Five-year probabilities for relapse and failure-free survival were 32% and 62%, respectively. High-dose consolidation with paclitaxel, carboplatin, and cyclophosphamide achieves a high failure-free survival in patients with high-risk breast cancer with acceptable toxicities and stable, long-term hematopoietic reconstitution. Evaluation of the benefit of high-dose therapy in these patients in larger prospective, randomized trials is warranted and currently under way.

Downloads

Download data is not yet available.

Downloads

Published

2000-01-01

How to Cite

Greinix, H. T., Linkesch, W., Seifert, M., Kubista, E., Czerwenka, K., Elahi, F., … Kalhs, P. (2000). Paclitaxel-containing High-dose Chemotherapy in High-risk Breast Cancer Patients. Acta Oncologica, 39(1), 47–52. https://doi.org/10.1080/028418600430969

Issue

Vol. 39 No. 1 (2000): Acta Oncologica

Section

Articles